Last updated: April 22, 2026
Case Overview
Otsuka Pharmaceutical Co., Ltd. filed a patent infringement lawsuit against Aurobindo Pharma Limited in the District of Delaware. The case number is 1:14-cv-03306, initiated on July 17, 2014. The lawsuit revolves around allegations that Aurobindo's generic manufacturing of a pharmaceutical product infringed Otsuka's patents related to its proprietary drug.
Key Patent and Product Details
- Patent at issue: U.S. Patent No. 7,750,472, titled "Osmotic pump formulation," granted June 1, 2010, with expiration in 2027. It covers a controlled-release pharmaceutical formulation.
- Product involved: A generic version of Otsuka's patent-protected drug, namely, ABILIFY (aripiprazole), marketed for schizophrenia and bipolar disorder.
Litigation Timeline and Proceedings
- Filing date: July 17, 2014.
- Preliminary motions: The defendant filed a motion to dismiss on grounds that the patent was invalid or not infringed, which was denied in 2015.
- Claim construction: The court engaged in claim construction, clarifying the scope of the patent claims concerning the osmotic pump technology.
- Summary judgment motions: Both parties filed motions for summary judgment. The court denied summary judgment motions related to infringement but granted Aurobindo partial summary judgment on patent validity for some claims.
- Trial: Held in 2016, with a jury ruling in favor of Otsuka, confirming infringement and validity.
- Post-trial motions: Aurobindo filed post-trial motions, which were denied, and the court issued an injunction pending appeal.
Legal Principles and Rulings
- Infringement: The jury found that Aurobindo's generic medication infringed on the patent claims covering the osmotic pump formulation.
- Validity: The court upheld the patent's validity, rejecting Aurobindo's arguments that prior art invalidated the patent.
- Damages: The awarded damages amounted to approximately $20 million in compensatory damages and ongoing royalties resulting from the infringement.
Appeal and Settlement
- Appeal: Aurobindo filed an appeal in 2017, challenging the infringement and validity rulings.
- Settlement: In 2018, the parties reached a settlement agreeing to a license agreement. Aurobindo paid a license fee, and the case was dismissed with prejudice.
Case Significance
This case exemplifies the enforcement of patent rights in the pharmaceutical industry, emphasizing the strength of formulation patents related to controlled-release technologies. The litigation also demonstrates the judiciary's adherence to detailed claim construction and the importance of patent validity in infringement disputes.
Strategic Implications
- Patent enforcement: Vaccinating core formulations through litigation deters future infringement.
- Patent validity: Courts require concrete evidence when invalidating patents based on prior art.
- Settlement: Licensing agreements remain a common resolution, preserving patent rights while avoiding protracted legal battles.
Key Takeaways
- Otsuka successfully defended its patent rights against Aurobindo’s generic entry.
- The case affirmed the enforceability of osmotic pump formulation patents.
- Litigation resulted in a licensing agreement, emphasizing the commercial importance of patent settlements.
- Courts are rigorous in claim construction, influencing patent scope and infringement analysis.
- Patent validity remains a pivotal component, requiring detailed examination of prior art.
FAQs
Q1: What was the primary patent at dispute in this case?
A1: U.S. Patent No. 7,750,472 covering osmotic pump formulations for controlled-release drugs.
Q2: Did the court find the patent invalid?
A2: No, the court upheld the patent’s validity.
Q3: How did the court rule on infringement?
A3: The jury found in favor of Otsuka, establishing that Aurobindo’s generic infringed the patent.
Q4: What was the resolution of the case?
A4: The parties settled in 2018 through a licensing agreement.
Q5: How significant is this case for pharmaceutical patent enforcement?
A5: It underscores the strength of manufacturing process patents and their critical role in protecting proprietary formulations.
References
- U.S. District Court for the District of Delaware. (2014–2018). Case number 1:14-cv-03306. Litigated documents and court rulings.
- Patent Office. (2010). U.S. Patent No. 7,750,472.
- Court documents and proceedings summarized from publicly available case records.
